Concepedia

Author

Pierre Feugier

Centre Hospitalier Régional et Universitaire de Nancy

Also Known As

Michele Cavo, P FEUGIER, P Feugier, P. Feugier, Pierre Feugier

69

Publications

800

Citations

10

H-Index

35

Concepts

All Affiliations

Centre Hospitalier Régional et Universitaire de NancyCHU Dijon BourgogneInsermUniversité de LorraineHospices Civils de Lyon
PF

About

Pierre Feugier is an author at Centre Hospitalier Régional et Universitaire de Nancy specializing in medicine, immunology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

435

2

Cell Biology

2

2

99

3

Health Sciences

1

1

28

4

Cellular Therapies

1

1

78

5

Clinical Nutrition

1

1

28

Pierre Feugier

×

11

Publications

707

Citations

10

H-Index

YearCitations

Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials

Maja V. Maraldo, Francesco Giusti, Ivan R. Vogelius,

The Lancet Haematology

2015

163

Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with <scp>non‐Hodgkin</scp> lymphoma treated with B‐cell depleting immunotherapy

Rémy Duléry, Sylvain Lamure, Marc Delord,

American Journal of Hematology

2021

156

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

Roberta Di Blasi, Steven Le Gouill, Emmanuel Bachy,

Blood

2022

131

Human mesenchymal stem cells improve ex vivo expansion of adult human CD34+ peripheral blood progenitor cells and decrease their allostimulatory capacity

Na Li, Pierre Feugier, Brigitte Serrurrier,

Experimental Hematology

2007

78

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R<sup>2</sup>) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

Franck Morschhauser, Loretta J. Nastoupil, Pierre Feugier,

Journal of Clinical Oncology

2022

61

Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells

Jean Galtier, Laëtitia Vercellino, Loïc Chartier,

Haematologica

2022

34

Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia?

Lauriane Filliatre‐Clement, Julien Broséus, Marc Müller,

Hematological Oncology

2018

28

Human umbilical vein endothelial cells increase ex vivo expansion of human CD34+ PBPC through IL-6 secretion

N. Li, Assia Eljaafari, Danièle Bensoussan,

Cytotherapy

2006

21

Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.

Charles Herbaux, Olivier Casasnovas, Pierre Feugier,

Journal of Clinical Oncology

2020

14

Prospective, Multicentric Phase II Randomized Trial Comparing the Efficacy of Methotrexate or Cyclophosphamide in Large Granular Lymphocytic Leukemia: A French National Study. Report on the Interim Analysis

T. Lamy, Cédric Pastoret, Roch Houot,

Blood

2019

11

Page 1